Jinfang Zhang

Jinfang Zhang

Auto-generated profile, based on publicly available information

Jinfang Zhang

Department of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2020 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
YGYang Gao
Yang Gao
NNNaoe Taira Nihira
Naoe Taira Nihira
XBXia Bu
Xia Bu
CCChen Chu
Chen Chu
JZJinfang Zhang
Jinfang Zhang
WWWenyi Wei
Wenyi Wei

10 April 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
HLHaiou Li
Haiou Li
YSYishuang Sun
Yishuang Sun
YYYingmeng Yao
Yingmeng Yao
SKShanwen Ke
Shanwen Ke
NZNannan Zhang
Nannan Zhang
JZJinfang Zhang
Jinfang Zhang
Ferroptosis is an iron-dependent type of regulated cell death resulting from extensive lipid peroxidation and plays a critical role in various physiological and pathological processes. However, the regulatory mechanisms for ferroptosis sensitivity remain incompletely understood. Here, we report that homozygous deletion of Usp8 (ubiquitin-specific protease 8) in intestinal epithelial cells (IECs) leads to architectural changes in the colonic epithelium and shortens mouse lifespan accompanied by increased IEC death and signs of lipid peroxidation. However, mice with heterozygous deletion of Usp8 in IECs display normal phenotype and become resistant to azoxymethane/dextran sodium sulfate–induced colorectal tumorigenesis. Mechanistically, USP8 interacts with and deubiquitinates glutathione peroxidase 4 (GPX4), leading to GPX4 stabilization. Thus, USP8 inhibition destabilizes GPX4 and sensitizes cancer cells to ferroptosis in vitro. Notably, USP8 inhibition in combination with ferroptosis inducers retards tumor growth and enhances CD8 + T cell infiltration, which potentiates tumor response to anti-PD-1 immunotherapy in vivo. These findings uncover that USP8 counteracts ferroptosis by stabilizing GPX4 and highlight targeting USP8 as a potential therapeutic strategy to boost ferroptosis for enhancing cancer immunotherapy.

31 March 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
WXWenjun Xiong
Wenjun Xiong
XGXueliang Gao
Xueliang Gao
TZTiantian Zhang
Tiantian Zhang
BJBaishan Jiang
Baishan Jiang
MHMing-Ming Hu
Ming-Ming Hu
JZJinfang Zhang
Jinfang Zhang
Anti-PD-1/PD-L1 immunotherapy has achieved impressive therapeutic outcomes in patients with multiple cancer types. However, the underlined molecular mechanism(s) for moderate response rate (15–25%) or resistance to PD-1/PD-L1 blockade remains not completely understood. Here, we report that inhibiting the deubiquitinase, USP8, significantly enhances the efficacy of anti-PD-1/PD-L1 immunotherapy through reshaping an inflamed tumor microenvironment (TME). Mechanistically, USP8 inhibition increases PD-L1 protein abundance through elevating the TRAF6-mediated K63-linked ubiquitination of PD-L1 to antagonize K48-linked ubiquitination and degradation of PD-L1. In addition, USP8 inhibition also triggers innate immune response and MHC-I expression largely through activating the NF-κB signaling. Based on these mechanisms, USP8 inhibitor combination with PD-1/PD-L1 blockade significantly activates the infiltrated CD8+T cells to suppress tumor growth and improves the survival benefit in several murine tumor models. Thus, our study reveals a potential combined therapeutic strategy to utilize a USP8 inhibitor and PD-1/PD-L1 blockade for enhancing anti-tumor efficacy.

15 July 2020 in Cell Research
Verified
Journal Article
Closed access
PDF file
JLJing Liu
Jing Liu
YPYunhua Peng
Yunhua Peng
LSLe Shi
Le Shi
Lixin WanLixin Wan
Lixin Wan
HIHiroyuki Inuzuka
Hiroyuki Inuzuka
WWWenyi Wei
Wenyi Wei

1 September 2021 in Trends in Cancer
Verified
Journal Article
Closed access
WXWenjun Xiong
Wenjun Xiong
YGYang Gao
Yang Gao
WWWenyi Wei
Wenyi Wei
JZJinfang Zhang
Jinfang Zhang

19 May 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
XXXiangling Xiao
Xiangling Xiao
JSJie Shi
Jie Shi
CHChuan He
Chuan He
XBXia Bu
Xia Bu
YSYishuang Sun
Yishuang Sun
JZJinfang Zhang
Jinfang Zhang
The programmed cell death protein 1 (PD-1) is an inhibitory receptor on T cells and plays an important role in promoting cancer immune evasion. While ubiquitin E3 ligases regulating PD-1 stability have been reported, deubiquitinases governing PD-1 homeostasis to modulate tumor immunotherapy remain unknown. Here, we identify the ubiquitin-specific protease 5 (USP5) as a bona fide deubiquitinase for PD-1. Mechanistically, USP5 interacts with PD-1, leading to deubiquitination and stabilization of PD-1. Moreover, extracellular signal-regulated kinase (ERK) phosphorylates PD-1 at Thr234 and promotes PD-1 interaction with USP5. Conditional knockout of Usp5 in T cells increases the production of effector cytokines and retards tumor growth in mice. USP5 inhibition in combination with Trametinib or anti-CTLA-4 has an additive effect on suppressing tumor growth in mice. Together, this study describes a molecular mechanism of ERK/USP5-mediated regulation of PD-1 and identifies potential combinatorial therapeutic strategies for enhancing anti-tumor efficacy.